Understanding BTBGD: An Overview for Families
At a Glance
BTBGD is a rare inherited disorder in which changes in SLC19A3 limit thiamine delivery to the brain. Symptoms can worsen during illness, but early, lifelong high-dose thiamine, often with biotin, may improve symptoms and help prevent permanent basal ganglia damage.
Receiving a diagnosis of Biotin-Thiamine-Responsive Basal Ganglia Disease (BTBGD) can be overwhelming for any parent or patient. You have likely spent weeks or months searching for answers to your or your child’s symptoms, only to be met with a complex genetic name. While the diagnosis is rare, it is also one of the most significant success stories in pediatric neurology because it is highly treatable when caught early [1][2].
BTBGD is an autosomal recessive genetic condition, meaning a person must inherit one changed (mutated) copy of the SLC19A3 gene from each parent to be affected [1]. This gene is responsible for creating a “gatekeeper” protein called thiamine transporter 2 (hTHTR2), which is the primary way your brain gets thiamine (Vitamin B1) out of the blood and into the cells that need it [3][4].
Why Thiamine Matters: An “Energy Crisis”
To understand BTBGD, it helps to think of the brain as an engine that runs on fuel. Its primary fuel is sugar (glucose). For the brain to turn that sugar into energy, it requires thiamine as a vital cofactor [5].
In people with BTBGD, the SLC19A3 mutation impairs the thiamine transporter. Even if you eat a diet rich in Vitamin B1, the main “gate” to the brain is compromised, and cellular availability of thiamine decreases [6]. This leads to a state where the brain is struggling for energy, even though the rest of the body may have plenty [7].
Without this cofactor, the brain cannot process carbohydrates correctly. This can sometimes cause a buildup of waste products like lactate or pyruvate in the brain and spinal fluid, though these laboratory findings are variable and not required for a diagnosis [8][9]. This “energy crisis” is why symptoms often appear or get worse during times of stress—like a high fever, an infection, or a minor injury—when the brain’s demand for energy suddenly spikes [10].
The Different Faces of BTBGD
BTBGD does not look the same in every person, and SLC19A3-related disease represents a continuous spectrum. Doctors generally group the condition into three broad patterns based on when symptoms first appear, though not every person fits one named category perfectly:
- Classical Childhood Onset (The most common form): Symptoms usually begin around age 4, though they can start anywhere from birth to age 12 [11]. It often starts with “episodes” where a child may seem confused, have trouble speaking (dysarthria), or experience involuntary muscle twisting and stiffening (dystonia) [1].
- Infantile Leigh-like Syndrome: This is a more severe, early-onset pattern appearing in the first few months of life [12]. It can involve seizures, poor feeding, and high levels of acid in the blood (lactic acidosis) [13]. It is often named after Leigh Syndrome because the clinical presentation is very similar.
- Adult-Onset: Though very rare, some people do not show symptoms until adulthood. This form can look like a sudden state of confusion, memory loss, or difficulty walking (ataxia) [14][15]. While much of this guide focuses on parents and children, these practical instructions and triggers apply equally to adult patients navigating self-management, work, and care.
Terminology Glossary
- Transporter: A protein that moves substances across a cell membrane.
- Cofactor: A “helper” molecule (like a vitamin) that proteins need to function properly.
- Phenotype: The observable characteristics or broad pattern of a disease.
- Pathogenic variant: A genetic mutation known to cause disease.
- Variant of Uncertain Significance (VUS): A genetic change whose relationship to disease is not yet known.
The Power of Early Treatment
The most important thing for families to know is that BTBGD is a treatable metabolic disorder. Because the main transporter to the brain is impaired, doctors use very high doses of thiamine to overcome this through alternative uptake mechanisms [16].
- Treatment is lifelong: Patients typically take high doses of oral thiamine and, often, biotin (Vitamin B7) [1].
- Rapid Improvement: In many cases, if treatment is started quickly after symptoms begin, children can see a dramatic or even substantial recovery of their skills [2].
- Preventing Damage: Regular treatment helps support the brain’s energy needs, which prevents the permanent scarring (lesions) in the basal ganglia—the part of the brain that controls movement—that gives the disease its name [17][1].
Because every child’s genetic makeup is slightly different, the exact dose and the way the disease progresses can vary even between siblings with the same mutation [18]. Working closely with a metabolic specialist to find the right balance for your child is the key to long-term health.
Common questions in this guide
What causes biotin-thiamine-responsive basal ganglia disease?
What symptoms can BTBGD cause in children and adults?
Can fever or infection make BTBGD symptoms worse?
How is BTBGD diagnosed?
How is BTBGD treated?
Can treatment improve symptoms or brain changes caused by BTBGD?
Get notified when new evidence is published on Biotin-thiamine-responsive basal ganglia disease.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.
References
References (18)
- 1
Biotin-Thiamine-Responsive Basal Ganglia Disease in Children: A Treatable Neurometabolic Disorder.
Saini AG, Sharma S
Annals of Indian Academy of Neurology 2021; (24(2)):173-177 doi:10.4103/aian.AIAN_952_20.
PMID: 34220059 - 2
Biotin-thiamine responsive basal ganglia disease: a retrospective review of the clinical, radiological and molecular findings of cases in Kuwait with novel variants.
Aburezq M, Alahmad A, Alsafi R, et al.
Orphanet journal of rare diseases 2023; (18(1)):271 doi:10.1186/s13023-023-02888-y.
PMID: 37670342 - 3
Biotin-thiamine responsive basal ganglia disease: Identification of a pyruvate peak on brain spectroscopy, novel mutation in SLC19A3, and calculation of prevalence based on allele frequencies from aggregated next-generation sequencing data.
Ferreira CR, Whitehead MT, Leon E
American journal of medical genetics. Part A 2017; (173(6)):1502-1513 doi:10.1002/ajmg.a.38189.
PMID: 28402605 - 4
Structural insights into substrate binding of SLC19A3: Comparing inward-open and outward-open conformations.
Zhang E, Xu X, Liu J, et al.
International journal of biological macromolecules 2025; (333(Pt 1)):148878 doi:10.1016/j.ijbiomac.2025.148878.
PMID: 41205939 - 5
Impaired Thiamine Metabolism in Amyotrophic Lateral Sclerosis and Its Potential Treatment With Benfotiamine: A Case Report and a Review of the Literature.
Mann RH
Cureus 2023; (15(6)):e40511 doi:10.7759/cureus.40511.
PMID: 37333039 - 6
Genetic defects of thiamine transport and metabolism: A review of clinical phenotypes, genetics, and functional studies.
Marcé-Grau A, Martí-Sánchez L, Baide-Mairena H, et al.
Journal of inherited metabolic disease 2019; (42(4)):581-597 doi:10.1002/jimd.12125.
PMID: 31095747 - 7
Free-thiamine is a potential biomarker of thiamine transporter-2 deficiency: a treatable cause of Leigh syndrome.
Ortigoza-Escobar JD, Molero-Luis M, Arias A, et al.
Brain : a journal of neurology 2016; (139(Pt 1)):31-8 doi:10.1093/brain/awv342.
PMID: 26657515 - 8
Thiamine metabolism dysfunction syndrome 5 (THMD5) mimicking acute disseminated encephalomyelitis.
Thompson ZE, Boyd NK, Khoshnood MM, Santoro JD
American journal of medical genetics. Part A 2023; (191(12)):2868-2872 doi:10.1002/ajmg.a.63376.
PMID: 37589194 - 9
An atypical presentation in a child with propionic acidemia? Better think twice!
Burkhardt T, Kastor KL, Christ S, et al.
JIMD reports 2025; (66(2)):e12464 doi:10.1002/jmd2.12464.
PMID: 40078824 - 10
Biotin-thiamine-responsive basal ganglia disease: catastrophic consequences of delay in diagnosis and treatment.
Algahtani H, Ghamdi S, Shirah B, et al.
Neurological research 2017; (39(2)):117-125 doi:10.1080/01616412.2016.1263176.
PMID: 27905264 - 11
An unusually mild case of biotin-thiamine-responsive basal ganglia disease.
Lail G, Blaser S, Inbar-Feigenberg M
Molecular genetics and metabolism reports 2023; (37()):101004 doi:10.1016/j.ymgmr.2023.101004.
PMID: 38053933 - 12
Are diagnostic magnetic resonance patterns life-saving in children with biotin-thiamine-responsive basal ganglia disease?
Kamaşak T, Havalı C, İnce H, et al.
European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society 2018; (22(6)):1139-1149 doi:10.1016/j.ejpn.2018.06.009.
PMID: 30054086 - 13
Report of the Largest Chinese Cohort With SLC19A3 Gene Defect and Literature Review.
Wang J, Wang J, Han X, et al.
Frontiers in genetics 2021; (12()):683255 doi:10.3389/fgene.2021.683255.
PMID: 34276785 - 14
SLC19A3 Gene Defects Sorting the Phenotype and Acronyms: Review.
Alfadhel M, Tabarki B
Neuropediatrics 2018; (49(2)):83-92 doi:10.1055/s-0037-1607191.
PMID: 28962040 - 15
Biotin-Responsive Basal Ganglia Disease: Treatable Metabolic Disorder with SLC19A3 Mutation Presenting as Rapidly Progressive Dementia.
Oommen AT, Polavarapu K, Christopher R, Netravathi M
Neurology India 2022; (70(2)):733-736 doi:10.4103/0028-3886.344659.
PMID: 35532649 - 16
Thiamine transporter 2 is involved in high glucose-induced damage and altered thiamine availability in cell models of diabetic retinopathy.
Beltramo E, Mazzeo A, Lopatina T, et al.
Diabetes & vascular disease research 2020; (17(1)):1479164119878427 doi:10.1177/1479164119878427.
PMID: 31726874 - 17
High-dose thiamine prevents brain lesions and prolongs survival of Slc19a3-deficient mice.
Suzuki K, Yamada K, Fukuhara Y, et al.
PloS one 2017; (12(6)):e0180279 doi:10.1371/journal.pone.0180279.
PMID: 28665968 - 18
Single gene, two diseases, and multiple clinical presentations: Biotin-thiamine-responsive basal ganglia disease.
Kılıç B, Topçu Y, Dursun Ş, et al.
Brain & development 2020; (42(8)):572-580 doi:10.1016/j.braindev.2020.05.008.
PMID: 32600842
This page is for informational purposes only and does not constitute medical advice. A metabolic specialist or neurologist should guide genetic interpretation, dosing, and illness plans for BTBGD.